Riskpilot← Back to searchSign inGet full accessBIODANE PHARMA A/S
A/SActiveCVR 28310102Staushedevejen 10Manufacture of other food products n.e.c. · NACE 1089Est. 2004— employeeshttps://biodanepharma.com/
Revenue 2024
DKK 2,9M
-6% vs 2023
EBITDA margin
62.4%
+105% vs 2023
Equity ratio
67.6%
Financial strength
Net profit 2024
DKK 1,7M
+83% vs 2023
| Revenue | DKK 2,9M | -6% |
| EBITDA | DKK 1,8M | +105% |
| Net profit | DKK 1,7M | +83% |
| Total assets | DKK 3,4M | -20% |
| Equity | DKK 2,3M | -34% |
| Employees | — | — |
Legal name
BIODANE PHARMA A/S
CVR number
28310102
Legal form
Aktieselskab
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
29. december 2004
Share capital
DKK 552.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive virksomhed med handel, industri, håndværk og finansiering og anden i forbindelse hermed beslægtet virksomhed.
Address
Staushedevejen 10
Phone
+4575557411
Website
https://biodanepharma.com/
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 384 | 106 | 279 | 438 | 747 | 968 | 1.011 | 1.508 | 1.629 | 3.701 | 2.372 | 3.071 | 2.886 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 8 | -1.292 | -324 | -335 | 64 | 152 | -584 | 338 | 619 | 2.360 | 616 | 879 | 1.801 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 8 | -1.292 | -324 | -335 | 64 | 152 | -584 | 338 | 619 | 2.360 | 616 | 879 | 1.801 |
| Net financials | 3 | -9 | -7 | 3 | -23 | -20 | -15 | 8 | 22 | 73 | 136 | 275 | 316 |
| Profit before tax | 11 | -1.301 | -330 | -332 | 41 | 132 | -599 | 345 | 640 | 2.433 | 752 | 1.154 | 2.117 |
| Tax | 3 | -325 | -80 | -79 | 8 | 29 | -132 | 89 | 141 | 535 | 165 | 254 | 466 |
| Net profit | 8 | -977 | -250 | -253 | 33 | 103 | -467 | 257 | 500 | 1.898 | 586 | 900 | 1.651 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.182 | 607 | 1.103 | 839 | 947 | 2.065 | 1.477 | 1.775 | 2.427 | 5.033 | 5.351 | 4.283 | 3.437 |
| Equity | 714 | -263 | 987 | 734 | 767 | 1.869 | 1.402 | 1.659 | 2.159 | 4.056 | 4.643 | 3.543 | 2.322 |
| Long-term debt | 0 | 154 | -8 | -24 | -6 | -4 | 55 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 469 | 870 | 108 | 81 | 174 | 192 | 74 | 116 | 268 | 977 | 708 | 740 | 1.114 |
| Total debt | 469 | 870 | 108 | 81 | 174 | 192 | 74 | 116 | 268 | 977 | 708 | 740 | 1.114 |
EBITDA margin
62.4%
This company
15.8%
Market median
+295% vs market
20122024
Equity ratio
67.6%
This company
38.2%
Market median
+77% vs market
20122024
Return on equity
71.1%
This company
18.4%
Market median
+286% vs market
20122024
Net profit margin
57.2%
This company
8.1%
Market median
+606% vs market
20122024
Asset turnover
0.84×
This company
1.12×
Market median
+25% vs market
20122024
Debt / equity
0.48×
This company
0.62×
Market median
+23% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GK Chief Executive Officer | Chief Executive Officer | 2011 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2011 | — | — | |
| Chairman | 2011 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BIODAN A/S | Company | 100.0% | 100.0% | 2007 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
St. Flinterup ApS
BIODANE PHARMA A/S Board members of BIODANE PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gunner Kreutzer Jakobsen | Chief Executive Officer | 0 companies |
| Peter Gæmelke | Chairman | 0 companies |
| Flemming Torben Heden Knudsen | Board of Directors | 0 companies |
| Michael Prasanjit Baruah | Board of Directors | 0 companies |
| Rasmus Juhl Rasmussen | Board of Directors | 0 companies |
| Lars Jørgen Larsen | Chairman | 0 companies |